Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Henlius Reports First Fully Profitable Year After Past Losses

The Result Continues The Trend Of Increased Sales Growth

Executive Summary

After reporting losses for the past two years, the Chinese pharma announced the first full year of profitability on the back of continued sales of its commercialized assets.

You may also be interested in...



Henlius Raises Stakes In Denosumab Race With Phase I Completion

Shanghai Henlius Biotech announced the successful completion of a Phase I study of its biosimilar HLX14 to Prolia/Xgeva, paving the way for EU and US approval applications later in 2024.

Henlius Pursues Two-Pronged Approach In Quest For Novel ADCs

Moving decisively but not hurriedly, Henlius is taking a two-pronged approach to join the global ADC race. The first two molecules developed via its in-licensed novel linker-payload platform have entered the clinical stage, while its own proprietary programs are seeing steady R&D progress, the Chinese firm's head of early R&D tells Scrip in an interview.

Mallinckrodt Reports 2023 Results After Second Restructuring

Emerging out of its second Chapter 11 bankruptcy filing in the past four years, the company reported a slump in net sales despite positive signals in specific portfolios.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB153400

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel